Consensus statement on the use of immunomodulating drugs in Multiple Sclerosis;Actualización del consenso sobre el uso de drogas inmunomoduladoras en el tratamiento de la Esclerosis Múltiple en Argentina

Revista Neurologica Argentina

Volumn 28, Issue 1, 2003, Pages 55-57

  Correale, Jorge ^a   Betinelli, R ^b   Brizuela, J A ^b   Caceres F ^b   Carra, A ^b   Deri, N ^b   Fernandez Liguori N ^b   Garcea, O ^b   Onaha, P ^b   Rotta Escalante, R ^b   San Pedro, E ^b   Sinay, V ^b   Tarulla, A ^b   Vetere, S ^b  

^a Instituto de Investigaciones Neurologicas Raul Carrera   (Argentina)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE;

ARGENTINA; CLINICAL TRIAL; HUMAN; IMMUNOMODULATION; IMMUNOPHARMACOLOGY; MULTIPLE SCLEROSIS; PRACTICE GUIDELINE; REVIEW; TREATMENT INDICATION;

EID: 0037785170     PISSN: 03250938     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Martin R, McFarland HF. Immunology of Multiple Sclerosis and experimental allergic encephalomyelitis. In: Raine CS, McFarland HF, and Tourttelotte WW: Multiple Sclerosis: clinical and pathogenic basis, London: Chapman & Hall; 1997, p 221-42.
2. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bö L. Axonal transection in multiple sclerosis lesions. N Engl J Med 1998; 338: 278-85.
3. De Stefano N, Matthews PM, Fu L, Narayanan S, Stanley JA, Francis GS, et al. Axonal damage correlates with disability in patients with relapsing remitting multiple sclerosis: results of a longitudinal MR spectroscopy study. Brain 1998; 121: 1469-77.
4. IFNB Multiple Sclerosis Study Group. Interferon beta -1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-61.
5. IFNB Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group. Interferon beta -1b in the treatment of multiple sclerosis. Final outcome of the ramdomized controlled trial. Neurology 1995; 45: 1277-85.
6. Jacobs L, Cookfair D, Rudick R, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta -1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285-94.
7. Johnson K; Brooks B, Cohen J, Ford CC, Goldstein J, Lisak RP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology; 1995; 45: 1268-76.
8. Johnson K, Brooks B, Cohen J, Ford CC, Goldstein J, Lisak RP et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect of multiple sclerosis relapse rate and degree of disability. Neurology; 1998; 50: 701-8.
9. PRISMS Study Group. Randomized double-blind placebo-controlled study of interferon beta -1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-504.
10. The PRISMS (Prevention of Relapses and Disability by Interferon-β-1a subcutaneously in Multiple Sclerosis) Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: Long term efficacy of interferon-b-1a in relapsing MS. Neurology 2001; 56: 1628-36.
11. Paty D, Li D, UBC MS/MRI Study Group, IFNB Multiple Sclerosis Study Group. Interferon beta -1b is effective in relapsing-remitting multiple sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 662-7.
12. Simon J, Jacobs L, Campion M, Wende K, Simonian N, Cookfair DL, et al. Magnetic resonance studies of intramuscular interferon beta -1a for relapsing multiple sclerosis. Ann Neurol 1998; 43: 79-87.
13. Comi G, Filippi M, Wollinsky JS, and the European/Canadian glatiramer acetate study group. European/Canadian multicenter, double blind, randomised, placebo controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001; 49: 290-7.
14. Li D, Paty D, UBC MS/MRI Analysis Research Group, PRISMS Study Group. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon beta -1a in relapsing-remitting multiple sclerosis. Ann Neurol 1999; 44: 197-206.
15. European Study Group in Interferon beta -1b in Secondary Progressive MS. Placebo-controlled multicenter randomized trial of interferon beta -1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491-7.
16. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta -1a in MS (SPECTRIMS). Randomized controlled trial of interferon-beta-1a in secondary progressive MS. Neurology 2001; 56: 1496-1504.
17. Cohen JA, Cutter GR, Fisher JS, Goodman AD, Heindenreich FR, Kooijmans MF, et al. Benefit of interferon-beta-1a on MSFC progression in secondary progressive MS. Neurology 2002; 59: 679-87.
18. Goodkin DE and the North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in Secondary Progressive MS: Clinical and MRI results of a 3-year randomised controlled trial. Neurology 2000; 54: 2351.
19. Miller D, Molyneaux P, Barker G, MacManus DG, Moseley IF, Wagner, K, et al. Effect of interferon beta -1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. Ann Neurol 1999; 46: 850-9.
20. Wingerchuk DM, Noseworthy JH. Randomized controlled trials to asses therapies for multiple sclerosis. Neurology 2002; 58: S40-8.
21. Shekelle PG. Are appropiateness criteria ready for use in clinical practice?. New Eng J Med 2001; 344: 677-8.
22. National Multiple Sclerosis Society (NMSS). Disease management consensus statement. Disponible en Internet en www.nmss.org
23. Oger J, Freedman M. Consensus statement of the Canadian MS clinics network on: the use of disease modifying agents in multiple sclerosis. Can J Neurol Sci 1999; 26: 294.
24. Rieckmann P, Toyka K, The Austrian-German-Swiss Multiple Sclerosis Therapy Consensus Group (MSTCG). Escalating therapy of multiple sclerosis. Eur Neurol 1999; 42: 121-7.
25. Freedman MS, Blumhardt LD, Brochet B, Comi G, Noseworthy JH, Sandberg-Wollheim M, et al. International consensus statement on the use of disease-modifyng agents in multiple sclerosis. Mult Scler 2002; 8: 19-23.
26. Correale J, Patrucco L, Cristiano E, Bettinelli R, Carrá A, Deri N, et al. Consenso sobre el uso de drogas inmunomoduladoras en el tratamiento de la Esclerosis Múltiple en Argentina. Rev Neurol Arg 2000; 25: 142-5.